Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AstraZeneca’s AZD7442 reduced risk of symptomatic COVID-19 in trial

The monoclonal antibody met its primary endpoint in a Phase 3 study.

By Brian Buntz | August 23, 2021

AstraZenecaThe investigational antibody ​​AZD7442 from AstraZeneca (LON:AZN) fared well in the PROVENT study, reading the risk of developing symptomatic COVID-19 by 77% compared to placebo.

More than three-quarters of participants in the trial had comorbidities that could potentially reduce their immune response to vaccination.

“We need additional approaches for individuals who are not adequately protected by COVID-19 vaccines,” said Mene Pangalos, AstraZeneca’s executive vice president, biopharmaceuticals R&D. “We are very encouraged by these efficacy and safety data in high-risk people, showing our long-acting antibody combination has the potential to protect from symptomatic and severe disease, alongside vaccines.”

The company plans to share more data from the PROVENT clinical trial later this year.

The trial includes more than 5,000 participants recruited from the U.S., U.K., Spain, France and Bel­gium.

AZD7442 consists of two long-acting antibodies (LAAB). AstraZeneca believes it to be the first antibody combination that could provide durable protection against COVID-19.

AstraZeneca developed AZD7442 based on the B cells of convalescent patients.

The most successful COVID-19-specific monoclonal antibody to date is Regeneron’s REGEN-COV, which reduced the risk of symptomatic infection 81% in a recent study. It is unclear, however, how long that drug remains effective against SARS-CoV-2.

AZD7442 could offer up to 12 months of protection from COVID-19, AstraZeneca estimates.

The long-lasting capability “could be very important as an option for patients at high risk from COVID infection who have responded poorly to vaccination or who must take immune-suppressing treatment for other disease (cancer, post-transplant, autoimmune disease etc.),” said Penny Ward, an independent pharmaceutical physician. “Indeed, it could potentially be game-changing for these individuals, who are currently being advised to continue to shield despite being fully vaccinated.”

The drug is administered via a single intramuscular injection.

Although AstraZeneca has sold $1.2 billion worth of COVID-19 vaccine in the first half of 2021 alone, its vaccine is less popular than those from rivals Moderna and Pfizer.

The therapy appeared to be safe, with adverse event rates balanced between the placebo and AZD7442 groups.

Pangalos speculated that the product could win emergency use authorization by the end of the year.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: AstraZeneca, AZD7442, biopharmaceuticals, coronavirus, covid-19
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
How biosimulation and virtual trials can bust through clinical trial roadblocks
Complexity’s counterpoint: Understanding protocol optimization 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE